Randomized Trialvery high evidence
Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial.
Circulation·August 31, 2026·PMID 42670293
Why it mattersHigh-risk primary prevention patients often have residual mortality risk despite standard lipid-lowering therapy. This prespecified analysis provides robust evidence that evolocumab improves survival in this population, including those with high-risk diabetes, addressing a key gap in outcomes data for PCSK9 inhibitors.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled